- Home
- PETS vs PYXS Comparison
PETS vs PYXS Comparison
Compare PETS & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- PYXS
- Stock Information
- Founded
- PETS 1996
- PYXS 2018
- Country
- PETS United States
- PYXS United States
- Employees
- PETS N/A
- PYXS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- PYXS Health Care
- Exchange
- PETS Nasdaq
- PYXS Nasdaq
- Market Cap
- PETS 68.6M
- PYXS 75.0M
- IPO Year
- PETS N/A
- PYXS 2021
- Fundamental
- Price
- PETS $3.32
- PYXS $1.14
- Analyst Decision
- PETS Sell
- PYXS Strong Buy
- Analyst Count
- PETS 2
- PYXS 5
- Target Price
- PETS $3.35
- PYXS $9.00
- AVG Volume (30 Days)
- PETS 127.9K
- PYXS 736.0K
- Earning Date
- PETS 08-05-2025
- PYXS 08-13-2025
- Dividend Yield
- PETS N/A
- PYXS N/A
- EPS Growth
- PETS N/A
- PYXS N/A
- EPS
- PETS 0.02
- PYXS N/A
- Revenue
- PETS $247,010,000.00
- PYXS N/A
- Revenue This Year
- PETS N/A
- PYXS N/A
- Revenue Next Year
- PETS N/A
- PYXS N/A
- P/E Ratio
- PETS $194.56
- PYXS N/A
- Revenue Growth
- PETS N/A
- PYXS N/A
- 52 Week Low
- PETS $2.90
- PYXS $0.83
- 52 Week High
- PETS $6.85
- PYXS $5.39
- Technical
- Relative Strength Index (RSI)
- PETS 42.37
- PYXS 51.02
- Support Level
- PETS $3.32
- PYXS $1.04
- Resistance Level
- PETS $3.49
- PYXS $1.24
- Average True Range (ATR)
- PETS 0.15
- PYXS 0.08
- MACD
- PETS 0.01
- PYXS -0.00
- Stochastic Oscillator
- PETS 51.35
- PYXS 53.57
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.